Investing
The investment comes less than a year after the company launched with $9 million in funding, bringing its total raise to more than $25 million.
The company will use the funds to expand its cloud-based automation platform for providers and pharmaceutical companies.
It is now set to take on the international markets three years after its inception.
The South Korean company now plans to expand the application of its AI to diagnose other medical conditions, including heart and neurological disorders.
The continuous glucose monitoring biosensor platform will use the funds to scale its manufacturing, move toward regulatory approval and perform more clinical trials.
The company will use the funds to enter into strategic relationships with life sciences organizations focusing on oncology and specialty care.
Also, Lunit has completed its acquisition of breast screening AI company Volpara.
The company offers adults and children virtual care sessions with therapists, homework and educational content.
The Delaware-based company provides self-insured employers with data and strategies to reduce costs associated with prescription medications.
The company's stock price dropped after it released its first-quarter earnings and lowered its full-year guidance despite an increase in revenue.